Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
83.67
-3.49 (-4.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 92 |
| CEO | Marino Garcia |
Contact Details
Address: 7 Times Square, 43rd Floor New York, New York 10036 United States | |
| Phone | 929 999 4055 |
| Website | dianthustx.com |
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marino Garcia M.B.A. | President, Chief Executive Officer and Director |
| Edward G. Carr | Senior Vice President and Chief Accounting Officer |
| Judson Taylor | Senior Vice President and Head of Technical Operations |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations and Corporate Affairs |
| Adam M. Veness Esq. | Senior Vice President, General Counsel and Secretary |
| Kristina Maximenko | Chief People Officer |
| Rashieda Gluck | Head of Clinical Development Operations |
| Scott Nogi M.B.A. | Head of Business Operations |
| Debra Segal | Head of Regulatory Affairs |
| Polly Hanff | Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | SCHEDULE 13G | Filing |
| Apr 9, 2026 | 144 | Filing |
| Apr 9, 2026 | ARS | Filing |
| Apr 9, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2026 | 144 | Filing |
| Mar 31, 2026 | 144 | Filing |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 24, 2026 | 144 | Filing |
| Mar 12, 2026 | 144 | Filing |